My Profile

Search abstracts

Lewis Sheiner

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

Friday June 5
09:00-09:45 Registration and coffee
09:45-10:00 Welcome and Introduction
Morning program Chair: Jon Wakefield
10:00-10:20 Jon Wakefield Bayesian individualization via sampling-based methods
10:20-10:40 J Bennett, L Lacey, K Koch, A Bye Determination of the population pharmacokinetics of bismuth from GR122311X in healthy volunteers using the gibbs sampler bayesian method
10:40-11:00  L Harnisch, W Weber Population approach to nonlinear pharmacokinetics of a new drug under development
11:00-11:20 NJ Bruce, AH Thomson, HL Elliott Population pharmacokinetics of tacrolimus in liver transplant patients
11:20-11:40 M Karlsson, P Milligan, D Nichols Determination of relative potency for drug and metabolite in vivo
11:40-12:00 N Jonsson, JR Wade, G Almqvist, M Karlsson Discrimination between rival dosing histories
12:00-13:45 Lunch
Afternoon program PK/PD Chair: Leon Aarons:
13:45-14:10 D Hille, R Bruno, S Durrleman, LB Sheiner Relationship between the pharmacokinetics and the pharmacodynamics of taxotere in cancer patients
14:10-14:35 K Fattinger, D Verotta, HC Porchet, A Munafo, J-Y le Cotonnec, LB Sheiner Pharmacokinetic/-dynamic modeling of a bivariate control system: luteinizing hormone and testosterone response to GnRH antagonist antide
14:35-14:55 C Laveille, N Frey, G Lerebours, G Resplandy, R Jochemsen Population pharmacokinetic-pharmacodynamic of a new specific bradycardic agent: S-16257
14:55-15:15 S Marshall, HL Elliott, PA Meredith Prediction of simvastatin pharmacological response: a population analysis
15:15-15:45 Coffee break
Afternoon session II Population Toxicokinetics and Scaling from animal to man Chair: Eliane Fuseau
15:45-16:05 P Burtin, J van Bree, F Mentre, S Hensel, JL Steimer A prospective evaluation of sparse sampling for toxicokinetics in the course of drug development
16:05-16:25 V Cosson, E Fuseau, C Efthymiopoulos, A Bye From animal to man
16:25-16:45 W Weber, L Harnisch, M Zimmer, P Crause, B Katgely Optimization of a ''first dose in man study'' using a NONMEM model for mammals
16:45 - 17:30 Discussions and questions Chair: Lutz Harnisch
16:45-17:00 F Keller, D Zellner, T Frankewitsch, M Giehl  Population kinetics and individual drug dosage adjustment
17:30-18:30 Poster session I, Software demonstrations
20:00-24:00 Social Evening

Saturday June 10
Tutorial I Chair: France Mentré
09:30-09:45 H Hassani Stochastic model in the analysis of migraine data
09:45-10:30 F Rombout An industrial perspective: practical stages in model development
10:30-11:00 Coffee break
Tutorial II Chair: Gudrun Wallenstein
11:00-11:45 L Aarons Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies
11:45-12:00 H-J Röthig, W Weber Closing remarks
12:00-14:00 Poster session II, software demonstrations

Posters Friday (group I)

Study design
1. D Breilh, C Pobel, MC Saux
Non linear pharmacokinetics of ethanol Analysis of patients with NONMEM. study I
2. D Breilh, C Pobel, MC Saux
Non linear pharmacokinetics of ethanol Population model with NONMEM after an optimal sampling duration. study II
3. B Charpiat, V Broant, G Tissier, JM Sab, P Maire, RW Jelliffe
How many patients and blood levels for population pharmacokinetic analysis? a study with a one compartment model
4. AC Falcao, MM Fernandez de Gatta, A Dominguez-Gil, JM Lanao
Sampling strategies for population analysis: a theoretical study to support practical results obtained with caffeine in premature neonates
5. NS Houwing, F Rombout
Population pharmacokinetics: effect of sampling scheme on parameter estimation

Drug development
6. G Lockwood, G Maier
The use of population pharmacokinetic approaches to aid in the assessment of bioequivalence for a highly variable drug
7. M Looby, U Wuenscher, M Weiss
NONMEM in destructive sampling experiments: experiences with the toxicokinetics of dibromchloromethane
8. F Mesnil, F Mentre, C Dubruc, A Mallet
Population pharmacokinetics analysis of mizolastine: estimation with NPML and validation
9. P Milligan, M Karlsson, D Nichols
High variability compounds - high risk for developers?
10. JPR Monteleone, NHG Holford
Modeling interoccasion variability in toxicokinetics and toxicodynamics

Data rich situations
11. R Schoemaker, A Cohen
Estimation of kinetic/dynamic curves with insufficient information for each individual using non-linear mixed effect modelling
12. J Wade, B-M Emanuelsson, LL Gustafsson, M Karlsson
A population approach enables the characterisation of saturable protein binding for Ropivacaine
13. W Weber, L Harnisch, M Zimmer, C Rokitta, P Mendes
New evidence for a triexponential disposition of Cefotaxim

Software demonstrations
1. M Tod
An algorithm for the estimation of optimal sampling times in pharmacokinetics by the ed, eid and api criteria
2. S Urien
MP2 (Micropharm population): a Windows application for population pharmacokinetics
3. J Wakefield, G Strehlau
Software product POPKAN; population pharmacokinetic modelling and analysis

Posters Saturday (group II)

14. D Breilh, C Pobel, C Roth, MC Saux, G Janvier
Sufentanyl Pharmacokinetic-pharmacodynamic modeling (PK/PD) on NONMEM in 10 patients with coronary surgery
15. MJ du Preez, JH Botha, ML McFadyen, M Adhikari Effect concentration relationships of theophylline in apnoea of prematurity
16. S Rietbrock, S Harder, H Baas
Influence of apomorphine on the PK/PD-relationship of levodopa: two-step versus NONMEM analysis

17. D Breilh, C Pobel, P Rispal, MC Saux
Population of vancomycine with continuous infusion administered in neutropenic patients modeling on NPEEM2-NONMEM-P-PHARM
18. J Bres, D Cupissol, J Nouguier-Soule, C Gestin-Boyer, Ü Büttner, B Palomba
Population distribution of platinum pharmacokinetic parameters for dosage recommendations of CDDP and adaptive control during the course of therapy, using different softwares
19. MT Mateu-Garcia, JJ Porez-Ruixo, VG Casabo-Alos, NV Jimenez-Torres Apache II as predictor of gentamicin pharmacokinetic parameters in critical ill patients
20. H Peyriere, J Bres, D Hillaire-Buys
Performance evaluation of three softwares for bayesian predictions of teicoplanin pharmacokinetic parameters: Apis Micropharm, PKS Abbott
21. D Santos Buelga, MF Delgado Iribarnegaray, MJ Garca, MJ Otero, A Falcao, A Dominguez-Gil
Carbamazepine population pharmacokinetics in children
22. M Tod, C Padoin, C Minozzi, J Cougnard, O Petitjean
A population pharmacokinetic study of isepamicin in ICU patients

23. LS Murray, DI Jodrell, JG Morrison, AW Kelman, DJ Kerr, B Whiting, SB Kaye
A population approach to predicting post-treatment levels of epirubicin in patients with advanced breast cancer
24. M Sandström, A Freijs, R Larsson, P Nygren, J Bergh, M-L Fjollskog, M Karlsson
Lack of relationship between systemic exposure for the component drugs of the FEC regimen in breast cancer patients
24. B Tranchand, S Urien, CJ Ardiet Population pharmacokinetics of intravenous melphalan: NONMEM and MP2 analysis